At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 128 enrolled
Drug / intervention
Efruxifermin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)
In Brief
A Phase 2 clinical trial evaluating Efruxifermin and Placebo for NASH - Nonalcoholic Steatohepatitis. Completed, enrolled 128 participants across 55 sites in 2 countries.
Detailed Summary
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in non-cirrhotic subjects with biopsy-proven F2 - F3 NASH.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNASH - Nonalcoholic Steatohepatitis
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartFeb 2021
First PostedFeb 2021
Primary CompletionMay 2024
TodayJul 2026
First PostedFeb 23, 2021
Enrollment StartFeb 16, 2021
Primary CompletionMay 2, 2024
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 5.4 years ago
Interventions
Efruxifermindrug
subcutaneous injection
Placebodrug
subcutaneous injection